Literature DB >> 32067849

Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy.

Andrew C Johns1, Chad Sorenson2, Alan Rogers2, Julia L Agne3, Desmond M D'Souza4, Jishu K Das5, Majd Issa5, Gina Perna5, Terence M Williams6, Alexa Meara7, Trevor Kitchin8, Karl E Haglund6, Dwight H Owen5.   

Abstract

Entities:  

Keywords:  Hydroxychloroquine; Hypertrophic pulmonary osteoarthropathy; Immune checkpoint inhibitors; Lung cancer; Pain

Mesh：

Substances：

Year:  2020        PMID： 32067849      PMCID： PMC7315373          DOI： 10.1016/j.cllc.2020.01.004

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  7 in total

1.  MR findings in pulmonary hypertrophic osteoarthropathy.

Authors:  A Capelastegui; E Astigarraga; C García-Iturraspe
Journal:  Clin Radiol       Date:  2000-01       Impact factor: 2.350

2.  Hypertrophic Pulmonary Osteoarthropathy: A Rare But Treatable Condition in Palliative Medicine.

Authors:  Mehdi Pourmorteza; Steven J Baumrucker; Ahmed Al-Sheyyab; Marco A C P Da Silva
Journal:  J Pain Symptom Manage       Date:  2015-02-17       Impact factor: 3.612

3.  Vascular endothelial growth factor and hypertrophic osteoarthropathy.

Authors:  L H Silveira; M Martínez-Lavín; C Pineda; M C Fonseca; C Navarro; A Nava
Journal:  Clin Exp Rheumatol       Date:  2000 Jan-Feb       Impact factor: 4.473

4.  Mechanism of action of hydroxychloroquine as an antirheumatic drug.

Authors:  R I Fox
Journal:  Semin Arthritis Rheum       Date:  1993-10       Impact factor: 5.532

Review 5.  Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature.

Authors:  Qingping Yao; Roy D Altman; Ernest Brahn
Journal:  Semin Arthritis Rheum       Date:  2008-08-29       Impact factor: 5.532

6.  Incidental solitary knee mass as the first manifestation of hidden lung cancer.

Authors:  Chin-Chiang Hsieh; Rong-Sen Yang; Kuo-Yuan Huang
Journal:  Knee       Date:  2008-11-13       Impact factor: 2.199

7.  PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

Authors:  Verena Rolfes; Christian Idel; Ralph Pries; Bernardo S Franklin; Barbara Wollenberg; Kirstin Plötze-Martin; Jens Habermann; Timo Gemoll; Sabine Bohnet; Eicke Latz; Julika Ribbat-Idel
Journal:  Oncotarget       Date:  2018-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.